Shared Decision-making for Selection of FDA-approved Therapies for NMOSD

Author(s):

Key Takeaways

Efficacy, safety, dosing frequency, and patient-specific factors are key in selecting NMOSD therapies.
Eculizumab and ravulizumab may be preferred for patients with severe relapses or contraindications to B-cell depletion.
Shared decision-making involves discussing treatment options, adverse effects, and aligning choices with patient preferences.

A panelist discusses how when treating NMOSD, neurologists should consider the patient's clinical characteristics, safety profiles, administration requirements, and cost-effectiveness when selecting between FDA-approved therapies such as eculizumab, inebilizumab, satralizumab, ravulizumab, and rituximab. Shared decision-making is crucial, involving close collaboration between the healthcare team and the patient to develop a personalized treatment plan that considers the patient's overall well-being.

What factors should be considered when choosing between other available FDA-approved therapies (eculizumab, inebilizumab, satralizumab, and ravulizumab) for patients with NMOSD?
What clinical characteristics can help guide neurologists in selecting eculizumab or ravulizumab versus rituximab?
Discuss shared decision-making when managing patients with APQ4+ NMOSD.